Jonsson, Philip

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,367

Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes

Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 866

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 667

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 643

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma

Xu, J., Reznik, E., Lee, H.-J., Gundem, G., Jonsson, P., Sarungbam, J., Bialik, A., Sanchez-Vega, F., Creighton, C. J., Hoekstra, J., et al. (2019) · eLife

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 43

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

Mondaca, S., Margolis, M., Sanchez-Vega, F., Jonsson, P., Riches, J. C., Ku, G. Y., Hechtman, J. F., Tuvy, Y., Berger, M. F., Shah, M. A., et al. (2019) · Gastric Cancer

Gastric Cancer Management and OutcomesHER2/EGFR in Cancer Research

Cited by 21